HR 7871 — MVP Act
Congress 119 · introduced 2026-03-09
Latest action: — Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
Sponsors
- Davis, Donald G. (D, NC-1) — cosponsor
Lobbied by (2)
LDA filings that named this bill in their activity descriptions. The lobbying firm (registrant) is paid by the client to lobby on this and related issues.
| Filing | Period | Registrant (lobbying firm) | Client | Income | Matched |
|---|---|---|---|---|---|
| 1st Quarter - Report | 2026 first_quarter | TIBER CREEK GROUP | ACADEMY OF MANAGED CARE PHARMACY | $80,000 | H.R. 7871 |
| 1st Quarter - Report | 2026 first_quarter | ORCHARD THERAPEUTICS NORTH AMERICA | ORCHARD THERAPEUTICS NORTH AMERICA | — | H.R. 7871 |
Action timeline
- · H11100 — Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
- · H11100 — Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
- · Intro-H — Introduced in House
- · 1000 — Introduced in House
Text versions
- Introduced in House · 2026-03-09 — open
Connected on the graph
Inbound (3)
| date | from | type | amount | role | source |
|---|---|---|---|---|---|
| — | Davis, Donald G. | cosponsor_of_bill | — | cosponsor | sponsorship |
| 2026-01-01 | ACADEMY OF MANAGED CARE PHARMACY | lobbies_on_bill | — | H.R. 7871 | lobbying_bill_mention |
| 2026-01-01 | ORCHARD THERAPEUTICS NORTH AMERICA | lobbies_on_bill | — | H.R. 7871 | lobbying_bill_mention |
Who matters
Members ranked by combined influence on this bill: role (sponsor 5 / cosponsor 1), capped speech count from the Congressional Record, and recorded-vote engagement.
| # | Member | Role | Speeches | Voted | Score |
|---|---|---|---|---|---|
| 1 | Davis, Donald G. (D, house NC-1) | cosponsor | 3 | — | 4 |
Who's influencing them
Orgs ranked by combined money flow on this bill: LDA filings citing the bill + individual contributions in cycle 2026from donors whose employer matches the org name (Schedule A) to any principal committee in the "who matters" list above.
| # | Org | LDA filings | LDA spend | Donor employees | Employee donations | Total |
|---|---|---|---|---|---|---|
| 1 | ACADEMY OF MANAGED CARE PHARMACY | 1 | $80,000 | 0 | $0 | $80,000 |
| 2 | not employed | 0 | $0 | 11 | $3,926 | $3,926 |
| 3 | method security | 0 | $0 | 1 | $3,500 | $3,500 |
| 4 | dragonfly | 0 | $0 | 1 | $3,500 | $3,500 |
| 5 | thorsen french advocacy | 0 | $0 | 2 | $3,000 | $3,000 |
| 6 | united states hispanic business counci | 0 | $0 | 1 | $2,500 | $2,500 |
| 7 | healthcare | 0 | $0 | 1 | $2,000 | $2,000 |
| 8 | martin fein interests, ltd. | 0 | $0 | 1 | $1,000 | $1,000 |
| 9 | cerity partners | 0 | $0 | 1 | $1,000 | $1,000 |
| 10 | gulf coast bag, inc. | 0 | $0 | 1 | $1,000 | $1,000 |
| 11 | raizner slania llp | 0 | $0 | 1 | $1,000 | $1,000 |
| 12 | the sterling group | 0 | $0 | 1 | $1,000 | $1,000 |
| 13 | self employed | 0 | $0 | 4 | $700 | $700 |
| 14 | peter damon group | 0 | $0 | 1 | $500 | $500 |
| 15 | harberg & huvard llp | 0 | $0 | 1 | $500 | $500 |
| 16 | smith-free group | 0 | $0 | 1 | $500 | $500 |
| 17 | capitol counsel | 0 | $0 | 1 | $500 | $500 |
| 18 | harberg + huvard llp | 0 | $0 | 1 | $500 | $500 |
| 19 | elco mutual | 0 | $0 | 1 | $250 | $250 |
| 20 | cambridge health alliance | 0 | $0 | 1 | $200 | $200 |
| 21 | washington university | 0 | $0 | 1 | $66 | $66 |
| 22 | federal communications commission | 0 | $0 | 1 | $25 | $25 |
| 23 | united airlines | 0 | $0 | 1 | $25 | $25 |
Predicted vote
Aggregated from: actual roll-call votes (when present) → sponsor → cosponsor → party median (predicts YES when ≥25% of the caucus sponsored/cosponsored). Each row labels its confidence tier so you can see why a position was predicted.
1 predicted yes (0%) · 280 predicted no (52%) · 262 unknown (48%)
By party: · R: 0 yes / 277 no · D: 1 yes / 0 no / 262 unknown · I: 0 yes / 3 no
1 high-confidence positions (voted + sponsor + cosponsor)
- Davis, Donald G. (D · house · NC-1) · cosponsor
Activity
Every typed-graph event involving this entity, newest first. Each row is one edge in the influence graph; click the date to jump to its provenance.
- 2026-05-17 · cosponsored by Davis, Donald G. (cosponsor) · sponsorship
- 2026-01-01 · lobbied on by ORCHARD THERAPEUTICS NORTH AMERICA (h.r. 7871) · lobbying_bill_mention
- 2026-01-01 · lobbied on by ACADEMY OF MANAGED CARE PHARMACY (h.r. 7871) · lobbying_bill_mention